Advances in Cancer Nanotheranostics for Experimental and Personalized Medicine

Author(s): Seda Keleştemur and Gamze Yeşilay

DOI: 10.2174/9789811456916120010009

Combining Imaging and Drug Delivery for Cancer Treatment

Pp: 131-149 (19)

Buy Chapters

* (Excluding Mailing and Handling)

  • * (Excluding Mailing and Handling)

Abstract

SHS investigation development is considered from the geographical and historical viewpoint. 3 stages are described. Within Stage 1 the work was carried out in the Department of the Institute of Chemical Physics in Chernogolovka where the scientific discovery had been made. At Stage 2 the interest to SHS arose in different cities and towns of the former USSR. Within Stage 3 SHS entered the international scene. Now SHS processes and products are being studied in more than 50 countries.

Abstract

Theranostics is the definition of bringing the imaging agent and therapeutic drug together in the same delivery design. The term ‘theranostic’ was first defined by John Funkhouser in 2002 and since then it became one of the most attractive fields in treatment of severe diseases. Nanoparticles (NPs) are the most suitable carrier systems due to their plasmonic and magnetic properties, active surface areas and various physicochemical properties. Development of therapeutic NPs provide both active and passive targeting, sensitive monitoring of biological circulation, effective drug carrying and releasing, longer circulation time and efficient clearance from renal system. Here in this chapter, we discussed commonly used cancer treatment theranostic NPs that utilize imaging modalities such as magnetic resonance imaging (MRI), radionuclidebased imaging; positron emission tomography (PET) and single-photon emission computed tomography (SPECT) and X-ray-computed tomography (CT).

Recommended Chapters

We recommend

Favorable 70-S: Investigation Branching Arrow

Authors:Bentham Science Books